Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV-FLEC: IV flecainide plus oral ranolazine vs IV flecainide for recent-onset atrial fibrillation
2024-514677-22-00Phase 3Completed
- Sponsor
- Win Medica
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Atrial fibrillation (AFib) comparing IV flecainide + oral ranolazine with IV flecainide monotherapy (2 arms). Primary endpoint: Conversion to sinus rhythm within 3 hours. Started Sep 2024; status: completed.
02
Drugs
flecainideranolazine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-514677-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514677-22-00.